Ocrelizumab
Ocrelizumab
Definition
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.
Also known as OCRELIZUMAB, PR070769, PRO-70769, PRO70769, rhuMAb 2H7, RO4964913 — per NCIT
Also identified as
- ATC L04AG08 per RXNORM
- NCIT NCIT:C66250 per NCIT
- SCTID 733464008 per RXNORM
- SCTID 763559000 per RXNORM
- UNII A10SJL62JY per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Multiple sclerosis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Central nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.